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Abstract The peptides corresponding to the four repeats found
in the microtubule binding region of tau protein were synthesized
and their ability for self-aggregation in presence of heparin or
chondroitin sulfate was measured. Mainly, only the peptide
containing the third tau repeat is able to form polymers in a high
proportion. Additionally, the peptide containing the second
repeat aggregates with a very low efficiency. However, when
this peptide contains the mutation (P301L), described in a fronto
temporal dementia, it is able to form polymers at a higher extent.
Finally, it is suggested to have a role for the first and fourth tau
repeats. It could be to decrease the ability of the third tau repeat
for self-aggregation in the presence of heparin.
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1. Introduction
Tau was ¢rst isolated as a microtubule associated protein,
since it co-puri¢es with microtubules [1,2] and stabilizes those
polymers [3,4].
The binding of tau to microtubules was found to be
through speci¢c microtubule binding domains. These domains
are three or four imperfectly repeated sequences of 31 or 32
residues located in the C-terminal half of the tau molecule [5^
7]. Additionally, the domains could be separated into two
regions, a highly conserved 18 amino acid repeat and a less
conserved region (13 or 14 residues) that composes the inter-
repeat domains [5,6,8,9]. The conserved repeated sequences
can bind to microtubules in vitro [10^12], although the inter-
repeat between repeat 1 and 2 has also a high microtubule
binding ability [13].
Tau protein, in modi¢ed form [14], is also the main com-
ponent of the aberrant ¢lament structures present in Alzheim-
er’s disease [15^18] and other diseases [19^21]. In these dis-
eases, modi¢ed tau (see for example, [22]) binds with lower
a⁄nity to microtubules than in controls and it self-aggregates
into aberrant structures, probably helped by other molecules
such as heparin [23^25]. The minimal sequence for that self-
interaction has also been studied and it was found that the
third repeat of tau protein could be involved in that interac-
tion [23].
Recently, some mutations in the tau gene have been iden-
ti¢ed in fronto temporal dementia and Parkinsonism linked to
chromosome 17 (FTDP-17) [26^29] and two of these muta-
tions were present in the ¢rst and second tubulin binding
repeats domains of tau.
In this work, we have studied the ability of the four tubulin
binding repeats to self-assemble into ¢laments. Additionally,
we have compared the previous results with those observed
using the peptides containing the FTDP-17 mutations present
in the tau repeats.
Our results indicate a di¡erent behavior for each repeat. Of
particular interest are the data for the peptide containing the
mutation P30IL, since it aggregates with a higher e⁄ciency
than its normal counterpart.
2. Materials and methods
2.1. Materials
Heparin and chondroitin sulfate B were obtained from Sigma. The
synthesis and puri¢cation of the tau peptides: VKSKIGSTENLK-
MQPGGG, corresponding to the ¢rst repeat; VKSKIGSTENLK-
HQPVGG, the mutated ¢rst repeat; VQSKCGSKDNIKHVPGGG,
the second repeat; VQSKCGSKDNIDHVLGGG, the mutated sec-
ond repeat; VTSKCGSLGNIHHKPGGG, the third repeat and
VQSKIGSLDNITHVPGGG, the fourth repeat, were performed as
indicated in [30].
Expression and puri¢cation of recombinant d protein and its frag-
ments (3R and 2R) were performed as described in [23].
2.2. Assembly of tau peptides into ¢laments
Filaments were grown by vapor di¡usion in hanging drops in the
standard way used for protein crystallization as previously indicated
[31]. In a typical experiment, 14 mg of d peptides were lyophilized and
resuspended in 10^15 Wl of bu¡er A (0.1 M MES (pH 6.4), 0.5 mM
MgCl2 and 2 mM EGTA) plus 50 mM NaCl in either the absence or
the presence (up to 1 mg/ml) of heparin. In other assays, a higher
amount of tau was used but, usually, it was tested at a concentration
of 1^10 mg/ml in the absence or presence of heparin or chondroitin
sulfate B [32]. The reservoir contained 0.2 M NaCl in bu¡er A. Fil-
aments were obtained after incubation for 4 days at 4‡C.
Aggregation of d peptides in presence of heparin was tested by
incubation of d at 1 mg/ml with increasing amounts of heparin
(0.5^5 mg/ml) for 4 days at 4‡C in a ¢nal volume of 20 Wl. Samples
were centrifuged for 30 min at maximal speed in an Airfuge (Beck-
man) and the protein present in the supernatant and pellet was ana-
lyzed by SDS-gel electrophoresis [23]. The amount of protein was
quanti¢ed by densitometry of the fractionated protein after Coomas-
sie brilliant blue staining of the gel and after comparing the results
obtained with those found for known amounts of bovine serum albu-
min, used as a control.
2.3. Electron microscopy
Samples were incubated on a carbon-coated grid for 2 min and then
stained with 2% (w/v) uranyl acetate for 1 min. Transmission electron
microscopy was performed in a JEOL model 1200EX electron micro-
scope operating at 100 kV. Electron micrographs were obtained at a
magni¢cation of 40 000 on a Kodak SO-163 ¢lm.
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3. Results
3.1. Polymerization of the peptides containing the di¡erent tau
repeats
It has been previously shown that a peptide containing the
sequence of the third tubulin binding domain (of the longest
human tau isotype [6]) is able to polymerize at a relative low
protein concentration in the presence of sulfated glycosami-
noglycans, such as heparin or chondroitin sulfate [23,25,32].
In order to complement the previous study, we have analyzed
the ability for self-aggregation of the other three tau repeats.
Fig. 1 shows that the peptide (3r) containing the third repeat
is the one showing a higher capacity for self-assembly. Addi-
tionally, the peptide containing the sequence for the second
repeat (2r) could also aggregate into polymers, in a very low
proportion (Fig. 2). No polymers were observed when the
peptides containing the sequences corresponding to the ¢rst
(1r) and fourth (4r) tau repeats were tested (Fig. 1, Fig. 2).
3.2. The role of tau repeats in the formation of tau polymers
Previous results suggest that the peptide containing the
third repeat of tau is mainly involved in the formation of
tau polymers and that the second repeat could also help, in
a lower proportion, to that aggregation. Thus, we wanted to
know if the ¢rst and fourth repeats may have any role in tau
aggregation.
In a previous study [23], it was observed, in a qualitatively
way, that the whole tau and tau fragments 3R (containing the
three repeats 1r, 3r, 4r of the smaller tau isotype), 2R (con-
taining the two ¢rst repeats (1r, 3r) of the same tau isotype)
and a peptide containing only the third repeat (3r), were all
able to polymerize into ¢brillar aggregates. Now, we have
performed a quantitative analysis of the ability for self-polym-
erization in the presence of heparin or chondroitin sulfate of
these di¡erent peptides (3R, 2R and 3r). When the same mo-
lar concentration was taken for the 3R, 2R and 3r samples,
we found that a much higher proportion of 3r peptide was
polymerized in comparison with the assembly of the other
peptides (Fig. 3). It suggests that the adjacent regions of 3r
peptide could play an inhibitory role in the ability of 3r pep-
tide for self-assembly and that upon deletion of those regions
that ability for 3r peptide polymerization increases. Since we
observed (see Fig. 1) that neither 1r peptide or 4r peptides
were able to self-aggregate, we suggest an inhibitory role of
those peptides (mainly 4r peptide) in tau aggregation (see Fig.
3), although it cannot be excluded that the inhibitory role is,
alternatively, due to the presence of the interrepeat sequences.
3.3. In£uence of FTDP-17 mutations in the polymerization of
tau peptides
Recently, two mutations in the tubulin binding domain of
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Fig. 1. Filaments assembled in vitro from the peptides containing
the sequences for the ¢rst (1r), second (2r), third (3r) and fourth
(4r) tau repeats (see Section 2). Bars indicate 200 nm.
Fig. 2. Aggregation of tau peptides in the presence of increasing
amounts of heparin. Tau peptides (1 mg/ml) containing the sequen-
ces for the ¢rst (F), the second (b), the third (a) and the fourth (F)
tau repeats were incubated with increasing amounts of heparin.
Polymerized peptides were quanti¢ed by centrifugation of the mix-
tures and measurement of the amount of peptide present in super-
natant and pellet was done as indicated in Section 2. The average
of three experiments is shown.
Fig. 3. (A) Schematic diagram of the whole tau molecule, the tau
fragment containing the three repeats (and interrepeats) present in
the smallest tau isoform (3R), the tau fragment containing the ¢rst
and second repeats (and interrepeats) (2R) and the tau fragment
containing only the third repeat (3r). (B) The aggregation of tau
fragments 3R, 2R and 3r (at 1 mg/ml) was measured in the presence
of heparin (1 mg/ml) as indicated in Fig. 2 and the result of that
measurement is indicated.
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the tau gene have been described in patients of familial fron-
totemporal dementia linked to chromosome 17 (FTDP-17
[26^29]). Since it is known that the brains of these patients
have tau ¢laments, we have tested if the presence of those
mutations, located in the ¢rst (1r) and the second (2r) repeats,
results in a higher ability for self-assembly of the peptides
containing those repeats. In the case of the peptide corre-
sponding to the ¢rst tau repeat, no main di¡erences were
observed in its capacity to polymerize either if glycine is
present instead of valine (G272V) (Fig. 4). Essentially, no
polymers were found in each case. However, in one experi-
ment (out of a total of four experiments) a polymer was ob-
served for the peptide containing the G272V mutation (the
lower panel in Fig. 4). Nevertheless, we don not think that
it could have an important relevance, since it appears to be an
exception.
However, in the case of the second repeat, the peptide con-
taining the mutation (P3O1L) shows a high level of polymer-
ization (in presence of heparin or chondroitin sulfate B) when
it was compared to its unmutated counterpart (Fig. 5). On the
other hand, the polymers obtained with the P301L mutant are
morphologically similar to those found for the peptide con-
taining the sequence for the third repeat (3r).
4. Discussion
The longest tau isotype [6] contains four imperfectly re-
peated sequences of 18 residues, separated by other less con-
served sequences (or interrepeats) [5]. Those repeats play a
role in the binding of tau to microtubules and it has been
described that the ¢rst, second and third repeat are able to
bind to microtubules in vitro, whereas no binding was ob-
served for the fourth repeat [10^13]. Moreover, Goode and
Feinstein (1994) found that the tau region containing the ¢rst
repeat, the interrepeat and the second repeat is probably the
one that is more implicated in the binding of tau to micro-
tubules. In a recent study, it has been indicated that a muta-
tion in the second repeat (P30IL), present in some FTDP-17
patients, decreases the binding of tau to microtubules [33].
In this work, we have studied the role of the tau repeats in
their ability for self-assembly. Our results suggest that the
third repeat is mainly involved in tau aggregation. This ob-
servation is compatible with the fact that PHF-like structures
could be assembled from fetal (containing 1r, 3r and 4r re-
peats) and adult (containing the four repeats) tau isoforms
[31,34,35]. Also, we found that the second repeat (only present
in adult tau) could facilitate tau assembly into polymers but in
much lower proportion and it is also compatible with the data
suggesting that an intronic mutation, present in some FTDP-
17 patients, may favor tau aggregation [33].
Additionally, it was found that the mutation in the second
repeat (P3O1L) facilitates tau aggregation, but a negligible
e¡ect on polymerization was observed when the peptide,
from the ¢rst repeat, containing the mutation G272V was
tested. Moreover, this peptide could probably have an inhib-
itory e¡ect on the aggregation of the third repeat. Thus, a
possible way to explain the consequences of this G272V mu-
tation is to consider that the change of a glycine for a valine
could result in a conformational change. A possibility could
be a decrease in the capacity to form a turn in the tau mol-
ecule. If such a turn takes place, a possible intramolecular
interaction, mediated by heparin, could be proposed and as
a consequence of that intramolecular interaction, the capacity
for intermolecular aggregation should decrease.
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Fig. 5. (A) Filaments assembled from tau peptides containing the
sequence for the second repeat, in the wild type form (W), or with
the mutation P310 L found in a FTDP-17 family. Bars indicate 200
nm. (B) The aggregation of the two peptides was measured as indi-
cated in Fig. 2 using a peptide concentration of 1 mg/ml and a hep-
arin:peptide ratio of 5:1 (weight:weight). The average of three ex-
periments is shown. A similar result was obtained when chondroitin
sulfate B was added to tau peptides at a ratio chondroitin:peptide
of 1:1 (weight:weight).
Fig. 4. Analysis for the assembly of tau peptides containing the se-
quence for the ¢rst repeat, in the wild type from (W), or with the
mutation G272V found in a FTDP-17 family. Bars indicate 200 nm.
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In summary, tau repeats play di¡erent roles. For self-assem-
bly, the most important element appears to be the third re-
peat, whereas for the binding of tau to microtubules, the
peptide containing the ¢rst two repeats appears to be the
one that is more involved in that interaction [13]. A mutation
in the second repeat may facilitate tau aggregation in a direct
way and also results in a decrease in its interaction with mi-
crotubules [33]. Finally, there is not an active role of the
fourth repeat in microtubule binding but it probably has an
inhibitory role in tau aggregation. Thus, a hypothetic tau
form in which repeat 3 is not expressing should probably
retain the microtubule binding capacity and will have a very
decreased capacity to form aberrant aggregates. In this way, it
can be hypothesized a possible therapeutical approach in
which a possible compound could speci¢cally block the third
repeat, avoiding tau aggregation without a¡ecting the micro-
tubule binding capacity of the other tau repeats.
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